Recruitment for an upcoming trial - Psilocybin for major depression: A randomised control trial

Psilocybin for major depression: A randomised control trial - the design of this trial is a DB-RCT in major depressive disorder. We will use fMRI to compare the treatment mechanisms of six weeks of daily Escitalopram (SSRI antidepressant) with two doses of psilocybin. The trial commenced as of January 2019 and the team are still recruiting for participants. Please read carefully the inclusion and exclusion criteria stated below.

It is essential that you meet these criteria:

1. Aged between 18-65
2. Currently suffering from moderate to severe depression. Mild depression or historical depression are not being looked at in this study
3. Able to reliably attend our campus in White City London on seven occasions (requiring seven days of leave from work)
4. Willing to take two doses of psilocybin and a six-week course of Escitalopram

Unfortunately, we cannot include you if:

1. You have a diagnosis of Emotionally Unstable (Borderline) personality disorder
2. You have a personal or immediate family history of psychosis (drug-induced psychosis, Schizophrenia, Bipolar). Bipolar disorder is not being looked at in this study
3. You are currently addicted to alcohol or any illicit drugs
4. You have taken a full course of Escitalopram in the past (please note that there is a similar medication called Citalopram which is fine to have taken)
5. You have epilepsy or any serious heart conditions

Please do note that the above criteria apply strictly.

We would advise that you only contact us if you are confident that you meet the stated criteria. Please contact us with any questions or to apply for a telephone screening on ashleigh.murphy@imperial.ac.uk. We will endeavour to contact you as soon as we can, but please note that due to the high volume of emails coming in there may be occasional delays.